Tardive Dyskinesia: Clinical Presentation and Treatment

Adler, 1999, Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group, Arch. Gen. Psychiatry, 56, 836, 10.1001/archpsyc.56.9.836 Alentorn, 2009, Pelvic dyskinesia with an outstanding response to tetrabenazine, Prog. Neuropsychopharmacol. Biol. Psychiatry, 33, 847, 10.1016/j.pnpbp.2009.03.033 APA (1992). Tardive dyskinesia: a task force report of the American Psychiatric Association. The American Psychiatric Association: Washington. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Barbui, 2006, Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries, Int. Clin. Psychopharmacol., 21, 355, 10.1097/01.yic.0000224785.68040.43 Bhoopathi, 2006, Benzodiazepines for neuroleptic-induced tardive dyskinesia, Cochrane Database Syst. Rev., 3, 10.1002/14651858.CD000205.pub2 Bouchard, 2010, Adult cases of congenital muscular torticollis successfully treated with botulinum toxin, Mov. Disord., 25, 2453, 10.1002/mds.23371 Boumans, 1994, Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, Schizophr. Bull., 20, 339, 10.1093/schbul/20.2.339 Broekema, 2007, Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study, Pharm. World Sci., 29, 126, 10.1007/s11096-006-9063-1 Bronstein, 2011, Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues, Arch Neurol., 68, 165, 10.1001/archneurol.2010.260 Bruscas, 2007, Tardive dyskinesia associated with clozapine treatment, Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 963, 10.1016/j.pnpbp.2007.01.016 Casey, 1990, Tardive dyskinesia, West J. Med., 153, 535 Casey, 2004, Pathophysiology of antipsychotic drug-induced movement disorders, J. Clin. Psychiatry, 65, 25 Casey, 2006, Implications of the CATIE trial on treatment: extrapyramidal symptoms, CNS Spectr., 11, 25, 10.1017/S1092852900026651 Chan, 2010, A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia, J. Clin. Psychiatry, 71, 1226, 10.4088/JCP.09m05155yel Chaplin, 1998, Informing patients about tardive dyskinesia. Controlled trial of patient education, Br. J. Psychiatry, 172, 78, 10.1192/bjp.172.1.78 Chaplin, 2002, Informing patients about tardive dyskinesia: four-year follow up of a trial of patient education, Aust. N. Z. J. Psychiatry, 36, 99, 10.1046/j.1440-1614.2002.00979.x Charles, 1997, Tongue protrusion dystonia: treatment with botulinum toxin, South Med. J., 90, 522, 10.1097/00007611-199705000-00012 Chong, 2001, Awareness of tardive dyskinesia in Asian patients with schizophrenia, J. Clin. Psychopharmacol., 21, 235, 10.1097/00004714-200104000-00017 Citrome, 2009, Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder, Schizophr. Res., 108, 238, 10.1016/j.schres.2008.11.017 Cohen, 2007, Deep brain stimulation of the internal globus pallidus for refractory tardive dystonia, Parkinsonism Relat. Disord., 13, 541, 10.1016/j.parkreldis.2006.11.007 Correll, 2008, Tardive dyskinesia and new antipsychotics, Curr. Opin. Psychiatry, 21, 151, 10.1097/YCO.0b013e3282f53132 Crow, 1983, Does tardive dyskinesia exist?, Mod. Probl. Pharmacopsychiatry, 21, 206, 10.1159/000408495 Dalack, 1998, Tardive dyskinesia, clozapine, and treatment response, Prog. Neuropsychopharmacol. Biol. Psychiatry, 22, 567, 10.1016/S0278-5846(98)00026-8 Damier, 2007, Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia, Arch. Gen. Psychiatry, 64, 170, 10.1001/archpsyc.64.2.170 de Haan, 2004, Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications, Can. J. Psychiatry, 49, 290, 10.1177/070674370404900503 De Haan, 2003, Subjective experience and d(2) receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study, Am. J. Psychiatry, 160, 303, 10.1176/appi.ajp.160.2.303 Duggal, 2007, Clozapine-induced tardive dystonia (blepharospasm), J. Neuropsychiatry Clin. Neurosci., 19, 86, 10.1176/appi.neuropsych.19.1.86 Ellison, 1992, Botulinum A toxin in spasmodic torticollis, Ann. Pharmacother., 26, 216 Eltahawy, 2004, Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report, Mov. Disord., 19, 969, 10.1002/mds.20092 Emsley, 2011, Subjective awareness of tardive dyskinesia and insight in schizophrenia, Eur Psychiatry., 26, 293, 10.1016/j.eurpsy.2009.12.006 Emsley, 2004, A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia, J. Clin. Psychiatry, 65, 696, 10.4088/JCP.v65n0516 Ertugrul, 2005, Clozapine-induced tardive dyskinesia: a case report, Prog. Neuropsychopharmacol. Biol. Psychiatry, 29, 633, 10.1016/j.pnpbp.2005.01.014 Espay, 2009, Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: an international survey of movement disorder society members, Mov. Disord., 24, 1366, 10.1002/mds.22618 Fenton, 2000, Prevalence of spontaneous dyskinesia in schizophrenia, J. Clin. Psychiatry, 61, 10 Fernandez, 2003, Classification and treatment of tardive syndromes, Neurologist, 9, 16, 10.1097/01.nrl.0000038585.58012.97 Freed, 1982, Tardive dyskinesia—subjective discomfort from psychosocial stress, S. Afr. Med. J., 62, 80 Gaebel, 1994, Intermittent medication—an alternative?, Acta Psychiatr. Scand., 89, 33, 10.1111/j.1600-0447.1994.tb05863.x Ganguly, 2004, Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000, J. Clin. Psychiatry, 65, 1377, 10.4088/JCP.v65n1013 Gill, 2010, Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm, Can. J. Neurol. Sci., 37, 631, 10.1017/S0317167100010817 Goldman, 1984, Intermittent neuroleptic therapy and tardive dyskinesia: a literature review, Hosp. Community Psychiatry, 35, 1215 Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs: Rockville, MD. Hennings, 2008, Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 1167, 10.1016/j.pnpbp.2007.09.010 Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics, Am. J. Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 Hyde, 2005, Tardive dyskinesia, 213 Jankovic, 1988, Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias, Neurology, 38, 391, 10.1212/WNL.38.3.391 Janno, 2004, Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients, Am. J. Psychiatry, 161, 160, 10.1176/appi.ajp.161.1.160 Jeste, 2000, Tardive dyskinesia in older patients, J. Clin. Psychiatry, 61, 27 Jeste, 2004, Tardive dyskinesia rates with atypical antipsychotics in older adults, J. Clin. Psychiatry, 65, 21 Jeste, 1988, Pharmacological treatments of tardive dyskinesia in the 1980 s, J. Clin. Psychopharmacol., 8, 38S Jeste, 1982, Therapeutic strategies against tardive dyskinesia. Two decades of experience, Arch. Gen. Psychiatry, 39, 803, 10.1001/archpsyc.1982.04290070037008 Jones, 2006, Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1), Arch. Gen. Psychiatry, 63, 1079, 10.1001/archpsyc.63.10.1079 Kahn, 2008, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial, Lancet, 371, 1085, 10.1016/S0140-6736(08)60486-9 Kane, 1993, Psychopharmacologic treatment of schizophrenia, Schizophr. Bull., 19, 287, 10.1093/schbul/19.2.287 Kane, 1986, Integrating incidence and prevalence of tardive dyskinesia, Psychopharmacol. Bull., 22, 254 Kapur, 2001, Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis, Am. J. Psychiatry, 158, 360, 10.1176/appi.ajp.158.3.360 Kefalopoulou, 2009, A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation, Acta Neurol. Scand., 119, 269, 10.1111/j.1600-0404.2008.01115.x Kenney, 2006, Is history of depression a contraindication to treatment with tetrabenazine?, Clin. Neuropharmacol., 29, 259, 10.1097/01.WNF.0000228369.25593.35 Kenney, 2006, Tetrabenazine in the treatment of hyperkinetic movement disorders, Expert Rev. Neurother., 6, 7, 10.1586/14737175.6.1.7 Koller, 2001, Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor, Mov. Disord., 16, 464, 10.1002/mds.1089 Koning, 2010, Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis, Schizophr. Bull., 36, 723, 10.1093/schbul/sbn146 Kruk, 1995, Neuroleptic-induced respiratory dyskinesia, J. Neuropsychiatry Clin. Neurosci., 7, 223, 10.1176/jnp.7.2.223 Lerner, 2007, Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study, J. Clin. Psychiatry, 68, 1648, 10.4088/JCP.v68n1103 Lerner, 2001, Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study, Am. J. Psychiatry, 158, 1511, 10.1176/appi.ajp.158.9.1511 Li, 2009, Clozapine-induced tardive dyskinesia in schizophrenic patients taking clozapine as a first-line antipsychotic drug, World J. Biol. Psychiatry, 10, 919, 10.1080/15622970802481895 Lieberman, 2007, An interview with Jeffrey A. Lieberman: tardive dyskinesia. [interview by Sussman Norman], CNS Spectr., 12, 747 Lieberman, 1991, The effects of clozapine on tardive dyskinesia, Br. J. Psychiatry, 158, 503, 10.1192/bjp.158.4.503 Lieberman, 2005, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, N. Engl. J. Med., 353, 1209, 10.1056/NEJMoa051688 Louza, 2005, Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years’ follow-up, J. Clin. Psychopharmacol., 25, 180, 10.1097/01.jcp.0000155823.59585.88 Macpherson, 1992, Tardive dyskinesia. Patients’ lack of awareness of movement disorder, Br. J. Psychiatry, 160, 110, 10.1192/bjp.160.1.110 Margolese, 2005, Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction, Can. J. Psychiatry, 50, 541, 10.1177/070674370505000907 McCreadie, 2002, Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up, Br. J. Psychiatry, 181, 135, 10.1192/bjp.181.2.135 Mejia, 2010, Tardive dyskinesia and withdrawal emergent syndrome in children, Expert Rev. Neurother., 10, 893, 10.1586/ern.10.58 Miyasaki, 2003, Psychogenic movement disorders, Can. J. Neurol. Sci., 30, S94, 10.1017/S0317167100003292 Mizrahi, 2007, Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia, Am. J. Psychiatry, 164, 630, 10.1176/appi.ajp.164.4.630 Nakamura, 1991, Three cases of respiratory dyskinesia, Jpn. J. Psychiatry Neurol., 45, 833 Nelson, 2003, Melatonin for the treatment of tardive dyskinesia, Ann. Pharmacother., 37, 1128, 10.1345/aph.1C460 Ondo, 1999, Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol, Am. J. Psychiatry, 156, 1279, 10.1176/ajp.156.8.1279 Paulsen, 1996, Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study, Psychopharmacology (Berl), 123, 307, 10.1007/BF02246639 Raguraman, 2007, Worsening of tardive dyskinesia due to clozapine therapy, J. Postgrad. Med., 53, 218, 10.4103/0022-3859.33874 Rao, 2010, Review article: metoclopramide and tardive dyskinesia, Aliment. Pharmacol. Ther., 31, 11, 10.1111/j.1365-2036.2009.04189.x Rapaport, 2000, Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia, Mov. Disord., 15, 352, 10.1002/1531-8257(200003)15:2<352::AID-MDS1030>3.0.CO;2-X Rathbone, 2006, Anticholinergics for neuroleptic-induced acute akathisia, Cochrane Database Syst. Rev., 10.1002/14651858.CD003727.pub3 Remington, 2010, Antipsychotic dosing: how much but also how often?, Schizophr. Bull., 36, 900, 10.1093/schbul/sbq083 Schilsky, 2009, Wilson disease: current status and the future, Biochimie, 91, 1278, 10.1016/j.biochi.2009.07.012 Schooler, 1982, Research diagnoses for tardive dyskinesia, Arch. Gen. Psychiatry, 39, 486, 10.1001/archpsyc.1982.04290040080014 Schrader, 2004, Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia, Mov. Disord., 19, 583, 10.1002/mds.10705 Shamir, 2001, Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study, Arch. Gen. Psychiatry, 58, 1049, 10.1001/archpsyc.58.11.1049 Shprecher, 2009, The management of tics, Mov. Disord., 24, 15, 10.1002/mds.22378 Silvestri, 2000, Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study, Psychopharmacology (Berl), 152, 174, 10.1007/s002130000532 Skidmore, 2005, Neuroleptic-induced tardive dyskinesia variants, 257 Slotema, 2008, Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 507, 10.1016/j.pnpbp.2007.10.004 Soares, 2001, Vitamin E for neuroleptic-induced tardive dyskinesia, Cochrane Database Syst. Rev., 10.1002/14651858.CD000203 Soares-Weiser, 2007, Tardive dyskinesia, Semin. Neurol., 27, 159, 10.1055/s-2007-971169 Soares-Weiser, 2006, Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia, Cochrane Database Syst. Rev., 10.1002/14651858.CD000459.pub2 Tammenmaa, 2004, Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials, Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, 1099, 10.1016/j.pnpbp.2004.05.045 Tamminga, 1994, Clozapine in tardive dyskinesia: observations from human and animal model studies, J. Clin. Psychiatry, 55, 102 Tarbox, 2006, Spontaneous dyskinesia and familial liability to schizophrenia, Schizophr. Res., 81, 125, 10.1016/j.schres.2005.09.013 Tauscher, 2004, Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics, Am. J. Psychiatry, 161, 1620, 10.1176/appi.ajp.161.9.1620 Tenback, 2006, Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study, Am. J. Psychiatry, 163, 1438, 10.1176/appi.ajp.163.8.1438 Tenback, 2010, Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia, J. Psychopharmacol., 24, 1031, 10.1177/0269881109106306 Tenback, 2009, Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis, Mov. Disord., 24, 2309, 10.1002/mds.22707 Trottenberg, 2005, Treatment of severe tardive dystonia with pallidal deep brain stimulation, Neurology, 64, 344, 10.1212/01.WNL.0000149762.80932.55 Tschopp, 2009, Botulinum toxin in painful tardive dyskinesia, Clin. Neuropharmacol., 32, 165, 10.1097/WNF.0b013e31818ddbc4 Turrone, 2003, The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats, Psychopharmacology (Berl), 165, 166, 10.1007/s00213-002-1259-z Turrone, 2005, Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats, Biol. Psychiatry, 57, 406, 10.1016/j.biopsych.2004.10.023 van Harten, 1998 van Harten, 1999, Acute dystonia induced by drug treatment, BMJ, 319, 623, 10.1136/bmj.319.7210.623 van Harten, 1998, Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III, Am. J. Psychiatry, 155, 565, 10.1176/ajp.155.4.565 van Harten, 2006, Botulinum toxin as a treatment for tardive dyskinesia, Mov. Disord., 21, 1276, 10.1002/mds.20904 van Harten, 1996, Use of clozapine in tardive dystonia, Prog. Neuropsychopharmacol. Biol. Psychiatry, 20, 263, 10.1016/0278-5846(95)00309-6 van Harten, 1996, The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I, Schizophr. Res., 19, 195, 10.1016/0920-9964(95)00096-8 Wiggelinkhuizen, 2009, Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease, Aliment. Pharmacol. Ther., 29, 947, 10.1111/j.1365-2036.2009.03959.x Yassa, 1986, Respiratory irregularity and tardive dyskinesia. A prevalence study, Acta Psychiatr. Scand., 73, 506, 10.1111/j.1600-0447.1986.tb02717.x Zhang, 2006, Deep brain stimulation in the treatment of tardive dystonia, Chin. Med. J. (Engl), 119, 789, 10.1097/00029330-200605010-00017